Developer docs
API playgroundTry for free, no card

Search company profiles

Relmada Therapeutics

Full company profile

uuid0002o7v

Namestring
Relmada Therapeutics
Legal namestring
Relmada Therapeutics, Inc.
Websiteurl
relmada.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Relmada Therapeutics is a clinical-stage biotechnology company developing therapies for oncology and central nervous system disorders, traded on NASDAQ under ticker RLMD and headquartered in Coral Gables, Florida. Its lead asset, NDV-01, is a sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) engineered for non-muscle invasive bladder cancer (NMIBC); the formulation enables approximately 10 days of controlled local drug release and in-office administration in under 5 minutes without anesthesia. NDV-01 reported 76% complete response at 12 months and 95% CR at any time in high-risk NMIBC patients, with 80% CR at 12 months in BCG-unresponsive disease and no observed progression to muscle-invasive disease; the program has FDA alignment on two registrational pathways (2L BCG-unresponsive and adjuvant intermediate-risk) and is advancing into the Phase 3 RESCUE registrational trial expected to initiate mid-2026. A provisional patent filed in April 2026 could extend exclusivity through 2047 if granted.

The company's second program, sepranolone, is a synthetic isoallopregnanolone that selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling; it targets compulsive behaviors in Prader-Willi syndrome, Tourette syndrome, and OCD, with a Phase 2 trial in Prader-Willi expected mid-2026. Both assets were in-licensed or acquired in 2025 (NDV-01 from Trigone Pharma; sepranolone from Sweden-based Asarina Pharma AB), marking a strategic pivot following prior Phase 3 setbacks with REL-1017 in major depressive disorder. The business model is pre-revenue: there are no approved products and no product sales, and the company funds operations through equity financings — approximately $410M raised across a December 2021 $150M public offering, a November 2025 $100M offering, and a March 2026 $160M PIPE with RA Capital, OrbiMed, Janus Henderson, and Venrock. The company reported $234M in cash as of March 31, 2026, with management stating runway through 2029, a $57.4M net loss for full-year 2025, and a Q1 2026 net loss of $19.1M. Future commercialization of NDV-01 is planned through specialty pharmacy networks serving academic and community urology practices.

Short descriptiontext

Relmada Therapeutics is a clinical-stage biotechnology company developing NDV-01, a sustained-release intravesical formulation for non-muscle invasive bladder cancer, and sepranolone, a GABA-A receptor modulator for CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCoral Gables, United States
HQ citystring
Coral Gables
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, bladder cancer therapy, CNS disorder treatment, pharmaceutical drug development, intravesical drug delivery
Industry2 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company. Intends to commercialize NDV-01 for non-muscle invasive bladder cancer and sepranolone for CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD upon regulatory approval.

relmada.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Relmada Therapeutics is a clinical-stage biotechnology company developing two lead product candidates: NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC) advancing toward a Phase 3 registrational program, and Sepranolone, a GABAA receptor modulator targeting compulsive behaviors in CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD. The company has no approved or commercial products and is pre-revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 76% complete response rate at 12 months in high-risk NMIBC patients
+4 more records
Product overview1 text field

Relmada Therapeutics is a clinical-stage biotechnology company developing two lead product candidates: NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer advancing into Phase 3 trials, and sepranolone, a GABAA receptor modulator targeting compulsive behaviors in CNS disorders including Prader-Willi syndrome. The company focuses on oncology and central nervous system disorders with an emphasis on delivering durable efficacy, favorable safety, and real-world usability.

Product and service2 records
1NDV-01
CategoryOncology pharmaceutical
Description

A sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) for the treatment of non-muscle invasive bladder cancer (NMIBC). Engineered for prolonged bladder retention and controlled drug release over approximately 10 days, enabling streamlined in-office administration in under 5 minutes without anesthesia or specialized equipment. Targets high-risk NMIBC patients who failed BCG therapy and intermediate-risk NMIBC patients in adjuvant setting.

2Sepranolone
CategoryCNS pharmaceutical
Description

A synthetic isoallopregnanolone that selectively antagonizes allopregnanolone (ALLO) at GABA-A receptors without disrupting general GABA signaling. Targets disorders linked to excess GABAergic activity including Prader-Willi syndrome, Tourette syndrome, and obsessive-compulsive disorder (OCD). Prior clinical and preclinical data support effects on food craving, appetite and compulsive behaviors.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-02-01
Description

Relmada acquired sepranolone, a Phase 2b-ready neurosteroid targeting GABA-A receptors, from Sweden-based Asarina Pharma AB in February 2025. Sepranolone targets compulsive behaviors for disorders including Prader-Willi syndrome, Tourette syndrome, and OCD. The acquisition expanded Relmada's CNS disorder portfolio.

Strategic tierCoreTypeTechnology or Integration
Description

Relmada licensed NDV-01, a Phase 2 bladder cancer candidate, from Trigone Pharma. NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer. This license agreement was key to Relmada's strategic pivot into oncology.

3Michael Quirk, PhD
Strategic tierKey AdvisorTypeOthers
Description

Appointed as Senior Advisor for sepranolone program in June 2026. Dr. Quirk brings over 20 years of neuroscience drug discovery experience, having served as Chief Scientific Officer and interim Head of R&D at Sage Therapeutics.

globenewswire.com
4Raj S. Pruthi, MD
Strategic tierKey AdvisorTypeOthers
Description

Chief Medical Officer of Relmada Therapeutics - Urology. Appointed to lead development of cancer treatment programs. Also serves on PreveCeutical Medical's board.

stocktitan.net
Strategic tierInvestor RelationsTypeOthers
Description

Investor relations contact for Relmada. Brian Ritchie from LifeSci Advisors serves as the primary IR contact for the company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of Ztalmy (ganaxolone), a neurosteroid acting on GABA-A receptors approved for seizures associated with CDKL5 deficiency disorder. Direct CNS neurosteroid peer comparable to sepranolone's GABA-A mechanism.

TypeDirect peer
Description

Clinical-stage biotech developing cretostimogene, an intravesical gene therapy for BCG-unresponsive NMIBC. Directly comparable to Relmada's NDV-01 program targeting the same patient population with overlapping treatment settings.

TypeDirect peer
Description

Developer of Anktiva (nogapendekin alfa), an IL-15 superagonist approved for BCG-unresponsive NMIBC. Direct competitor to NDV-01 in the same NMIBC treatment space with established regulatory and commercial footprint.

TypeDirect peer
Description

Developer of Adstiladrin (nadofaragene), an intravesical gene therapy approved for BCG-unresponsive NMIBC. Direct competitor to NDV-01 with similar mechanism of local bladder delivery in the same indication.

TypeDirect peer
Description

Developer of Zurzuvae (zuranolone), a neurosteroid acting on GABA-A receptors approved for postpartum depression. Closely comparable to sepranolone's GABA-A modulation mechanism; Senior Advisor Michael Quirk joined Relmada from Sage.

TypeBroad incumbent
Description

Large pharmaceutical company with KEYTRUDA (pembrolizumab) approved for BCG-unresponsive NMIBC. Competes with NDV-01 in the same indication but as part of a broader oncology portfolio rather than a focused NMIBC asset.

7Bristol Myers Squibb
TypeBroad incumbent
Description

Major oncology incumbent with Opdivo and a broad bladder cancer franchise. Competes in NMIBC and broader oncology but is a broad-line pharmaceutical player rather than a focused biotech.

TypeBroad incumbent
Description

Diversified healthcare incumbent with significant oncology and CNS franchises. Represents the strategic acquirer profile relevant to clinical-stage biotechs like Relmada, though not a direct product competitor in NMIBC.

TypeBroad incumbent
Description

Large pharmaceutical company with deep oncology and CNS pipelines. Relevant as a potential strategic acquirer and broad industry peer, but does not directly compete in NMIBC or sepranolone's CNS indications.

TypeOthers
Description

Swedish biotech from which Relmada acquired sepranolone in February 2025. Adjacent technology originator with prior expertise in sepranolone's GABA-A mechanism for CNS disorders.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Relmada Therapeutics

Biopharmaceuticalsrelmada.com

Relmada Therapeutics is a clinical-stage biotechnology company developing NDV-01, a sustained-release intravesical formulation for non-muscle invasive bladder cancer, and sepranolone, a GABA-A receptor modulator for CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD.

What Relmada Therapeutics does

Relmada Therapeutics is a clinical-stage biotechnology company developing therapies for oncology and central nervous system disorders, traded on NASDAQ under ticker RLMD and headquartered in Coral Gables, Florida. Its lead asset, NDV-01, is a sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) engineered for non-muscle invasive bladder cancer (NMIBC); the formulation enables approximately 10 days of controlled local drug release and in-office administration in under 5 minutes without anesthesia. NDV-01 reported 76% complete response at 12 months and 95% CR at any time in high-risk NMIBC patients, with 80% CR at 12 months in BCG-unresponsive disease and no observed progression to muscle-invasive disease; the program has FDA alignment on two registrational pathways (2L BCG-unresponsive and adjuvant intermediate-risk) and is advancing into the Phase 3 RESCUE registrational trial expected to initiate mid-2026. A provisional patent filed in April 2026 could extend exclusivity through 2047 if granted.

The company's second program, sepranolone, is a synthetic isoallopregnanolone that selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling; it targets compulsive behaviors in Prader-Willi syndrome, Tourette syndrome, and OCD, with a Phase 2 trial in Prader-Willi expected mid-2026. Both assets were in-licensed or acquired in 2025 (NDV-01 from Trigone Pharma; sepranolone from Sweden-based Asarina Pharma AB), marking a strategic pivot following prior Phase 3 setbacks with REL-1017 in major depressive disorder. The business model is pre-revenue: there are no approved products and no product sales, and the company funds operations through equity financings — approximately $410M raised across a December 2021 $150M public offering, a November 2025 $100M offering, and a March 2026 $160M PIPE with RA Capital, OrbiMed, Janus Henderson, and Venrock. The company reported $234M in cash as of March 31, 2026, with management stating runway through 2029, a $57.4M net loss for full-year 2025, and a Q1 2026 net loss of $19.1M. Future commercialization of NDV-01 is planned through specialty pharmacy networks serving academic and community urology practices.

Relmada Therapeutics firmographics

Firmographics
Name
Relmada Therapeutics
Legal name
Relmada Therapeutics, Inc.
Website
https://relmada.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Relmada Therapeutics is a clinical-stage biotechnology company developing NDV-01, a sustained-release intravesical formulation for non-muscle invasive bladder cancer, and sepranolone, a GABA-A receptor modulator for CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD.
Ownership category
akta.pro rank

Relmada Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Clinical-stage biotechnology
  • Bladder cancer therapy
  • CNS disorder treatment
  • Pharmaceutical drug development
  • Intravesical drug delivery

Where Relmada Therapeutics is headquartered

Location

Headquarters

HQ city
Coral Gables
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Relmada Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotechnology company. Intends to commercialize NDV-01 for non-muscle invasive bladder cancer and sepranolone for CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Relmada Therapeutics product offering

Product offering

Core offering

Relmada Therapeutics is a clinical-stage biotechnology company developing two lead product candidates: NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC) advancing toward a Phase 3 registrational program, and Sepranolone, a GABAA receptor modulator targeting compulsive behaviors in CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD. The company has no approved or commercial products and is pre-revenue.

Product overview

Relmada Therapeutics is a clinical-stage biotechnology company developing two lead product candidates: NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer advancing into Phase 3 trials, and sepranolone, a GABAA receptor modulator targeting compulsive behaviors in CNS disorders including Prader-Willi syndrome. The company focuses on oncology and central nervous system disorders with an emphasis on delivering durable efficacy, favorable safety, and real-world usability.

Differentiator

Problem solved

Functional benefit

Products and services

  • NDV-01 A sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) for the treatment of non-muscle invasive bladder cancer (NMIBC). Engineered for prolonged bladder retention and controlled drug release over approximately 10 days, enabling streamlined in-office administration in under 5 minutes without anesthesia or specialized equipment. Targets high-risk NMIBC patients who failed BCG therapy and intermediate-risk NMIBC patients in adjuvant setting.
  • Sepranolone A synthetic isoallopregnanolone that selectively antagonizes allopregnanolone (ALLO) at GABA-A receptors without disrupting general GABA signaling. Targets disorders linked to excess GABAergic activity including Prader-Willi syndrome, Tourette syndrome, and obsessive-compulsive disorder (OCD). Prior clinical and preclinical data support effects on food craving, appetite and compulsive behaviors.

Quantifiable outcome

  • 76% complete response rate at 12 months in high-risk NMIBC patients
  • +4 more outcomes

Companies that use Relmada Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Relmada Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Relmada Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, key advisor and investor relations.

  • Asarina Pharma ABcoreTechnology or Integration · 1 February 2025Relmada acquired sepranolone, a Phase 2b-ready neurosteroid targeting GABA-A receptors, from Sweden-based Asarina Pharma AB in February 2025. Sepranolone targets compulsive behaviors for disorders including Prader-Willi syndrome, Tourette syndrome, and OCD. The acquisition expanded Relmada's CNS disorder portfolio.
  • Trigone Pharma Ltd.coreTechnology or IntegrationRelmada licensed NDV-01, a Phase 2 bladder cancer candidate, from Trigone Pharma. NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer. This license agreement was key to Relmada's strategic pivot into oncology.
  • Michael Quirk, PhDkey advisorOthersAppointed as Senior Advisor for sepranolone program in June 2026. Dr. Quirk brings over 20 years of neuroscience drug discovery experience, having served as Chief Scientific Officer and interim Head of R&D at Sage Therapeutics.
  • Raj S. Pruthi, MDkey advisorOthersChief Medical Officer of Relmada Therapeutics - Urology. Appointed to lead development of cancer treatment programs. Also serves on PreveCeutical Medical's board.
  • LifeSci Advisorsinvestor relationsOthersInvestor relations contact for Relmada. Brian Ritchie from LifeSci Advisors serves as the primary IR contact for the company.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Relmada Therapeutics competitors and assessment

Company assessment

Direct peers

  • Marinus Pharmaceuticals: Developer of Ztalmy (ganaxolone), a neurosteroid acting on GABA-A receptors approved for seizures associated with CDKL5 deficiency disorder. Direct CNS neurosteroid peer comparable to sepranolone's GABA-A mechanism.
  • CG Oncology: Clinical-stage biotech developing cretostimogene, an intravesical gene therapy for BCG-unresponsive NMIBC. Directly comparable to Relmada's NDV-01 program targeting the same patient population with overlapping treatment settings.
  • ImmunityBio: Developer of Anktiva (nogapendekin alfa), an IL-15 superagonist approved for BCG-unresponsive NMIBC. Direct competitor to NDV-01 in the same NMIBC treatment space with established regulatory and commercial footprint.
  • Ferring Pharmaceuticals: Developer of Adstiladrin (nadofaragene), an intravesical gene therapy approved for BCG-unresponsive NMIBC. Direct competitor to NDV-01 with similar mechanism of local bladder delivery in the same indication.
  • Sage Therapeutics: Developer of Zurzuvae (zuranolone), a neurosteroid acting on GABA-A receptors approved for postpartum depression. Closely comparable to sepranolone's GABA-A modulation mechanism; Senior Advisor Michael Quirk joined Relmada from Sage.

Broad incumbents

  • Merck & Co. Large pharmaceutical company with KEYTRUDA (pembrolizumab) approved for BCG-unresponsive NMIBC. Competes with NDV-01 in the same indication but as part of a broader oncology portfolio rather than a focused NMIBC asset.
  • Bristol Myers Squibb: Major oncology incumbent with Opdivo and a broad bladder cancer franchise. Competes in NMIBC and broader oncology but is a broad-line pharmaceutical player rather than a focused biotech.
  • Johnson & Johnson: Diversified healthcare incumbent with significant oncology and CNS franchises. Represents the strategic acquirer profile relevant to clinical-stage biotechs like Relmada, though not a direct product competitor in NMIBC.
  • Pfizer: Large pharmaceutical company with deep oncology and CNS pipelines. Relevant as a potential strategic acquirer and broad industry peer, but does not directly compete in NMIBC or sepranolone's CNS indications.

Others

  • Asarina Pharma: Swedish biotech from which Relmada acquired sepranolone in February 2025. Adjacent technology originator with prior expertise in sepranolone's GABA-A mechanism for CNS disorders.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Relmada Therapeutics social profiles

Digital presence

Relmada Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Relmada Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Relmada Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Relmada Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Relmada Therapeutics

What does Relmada Therapeutics do?

Relmada Therapeutics is a clinical-stage biotechnology company developing two lead product candidates: NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC) advancing toward a Phase 3 registrational program, and Sepranolone, a GABAA receptor modulator targeting compulsive behaviors in CNS disorders including Prader-Willi syndrome, Tourette syndrome, and OCD. The company has no approved or commercial products and is pre-revenue.

Is Relmada Therapeutics a public or private company?

Relmada Therapeutics is a public company. It is classified as public and is currently operating.

When was Relmada Therapeutics founded?

Relmada Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is Relmada Therapeutics based?

Relmada Therapeutics is headquartered in Coral Gables, United States, in the North America region.

How does Relmada Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Relmada Therapeutics's main competitors?

Direct peers on record are Marinus Pharmaceuticals, CG Oncology, ImmunityBio, Ferring Pharmaceuticals and Sage Therapeutics. Broad incumbents are Merck & Co., Bristol Myers Squibb, Johnson & Johnson and Pfizer. Asarina Pharma is listed as an others.

Does Relmada Therapeutics have an API?

No public API is recorded for Relmada Therapeutics.

What industry is Relmada Therapeutics in?

Relmada Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterRelmada Therapeutics appoints Jørn Skibsted Jakobsen as CDORelmada Therapeutics appointed Jørn Skibsted Jakobsen as chief development officer for urology and uro-oncology. He will oversee clinical development, including the planned Phase III SPECTRUM registrational program for NDV-01.TradingViewRelmada Therapeutics Names Jørn Skibsted Jakobsen Chief Development OfficerRelmada Therapeutics appointed Jørn Skibsted Jakobsen as Chief Development Officer to lead clinical development, including NDV-01's planned Phase 3 SPECTRUM program. He previously led global clinical development for ADSTILADRIN, which received approvals in the U.S., Europe, Japan, and Canada. His appointment brings over 25 years of experience in urologic oncology and drug development.Investing.comRelmada appoints Jørn Jakobsen as chief development officerRelmada Therapeutics appointed Jørn Skibsted Jakobsen as Chief Development Officer for Urology & Uro-Oncology. He will lead clinical development of NDV-01, including the planned Phase 3 SPECTRUM registrational program. He previously led global clinical development for ADSTILADRIN at Ferring Pharmaceuticals.Business & FinancialRelmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, Phd, As Chief Development OfficerRelmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer for Urology & Uro-Oncology. He previously led Ferring's ADSTILADRIN program, which received FDA, EMA, PMDA, and Health Canada approvals for NMIBC. He will lead clinical development of NDV-01, including the planned Phase 3 SPECTRUM registrational program.GlobeNewswireRelmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development OfficerRelmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer for Urology & Uro-Oncology. He previously led Ferring's pivotal ADSTILADRIN program, which received FDA, EMA, PMDA, and Health Canada approvals for NMIBC. He will lead clinical development for NDV-01, including the planned Phase 3 SPECTRUM registrational program.Investing.comEarnings call transcript: Relmada Therapeutics narrows loss as cash runway extends in Q3 2026Relmada Therapeutics reported a Q3 2026 net loss of $13.9 million, or $0.12 per share, beating the expected $0.1396 loss. Cash and short-term investments rose to $202.1 million, funding operations through 2029. The company expects to file an IND for NDV-01 by year-end 2026 and begin phase III enrollment in Q1 2027.Defense WorldRelmada Therapeutics (RLMD) Expected to Announce Earnings on ThursdayRelmada Therapeutics is expected to report Q3 2026 earnings after market close on November 12th, with analysts projecting a loss of $0.1450 per share. The company's CFO purchased 79,800 shares at $4.25 each, increasing his stake by 8.67%. Analysts have a consensus price target of $12.00.GlobeNewswireRelmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026Relmada Therapeutics will host a conference call and webcast on November 12, 2026, at 4:30 PM ET to report Q3 2026 financial results and business progress. The call will cover the company's oncology and CNS therapies, including lead candidates NDV-01 and sepranolone.MarketBeatRelmada Therapeutics, Inc. (RLMD) - What Are Investment Firms Thinking About This Stock?Relmada Therapeutics shares received an average "Moderate Buy" rating from eight analysts, with a twelve-month price objective of $12.00. CFO Maged Shenouda bought 79,800 shares at $4.25, increasing his stake by 8.67%. Institutional investors hold 45.24% of the company.Ticker ReportRelmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Average Price Target of $12.00 According to BrokeragesRelmada Therapeutics shares have an average price target of $12.00 from eight analysts, with a Moderate Buy rating. The company reported Q2 EPS of -$0.11, beating the -$0.20 consensus, and CFO Maged Shenouda bought 120,200 shares at $4.20. Analysts forecast a fiscal-year EPS of -$0.62.